Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma (> 10 cm) with major portal vein tumor thrombosis: a multicenter propensity score matching analysis
Compared with HAIC alone, the combination of HAIC, lenvatinib, and toripalimab can effectively prolong the survival prognosis of patients with large HCC complicated by major PVTT and achieve intrahepatic and PVTT remission. It is a promising treatment approach.
Authors
- Fengtao Zhang (ORCID: https://orcid.org/0009-0003-7128-0126)
- Ran Yang (ORCID: https://orcid.org/0000-0003-3199-9104)
- Xiang‐Ran Cai (ORCID: https://orcid.org/0000-0003-4010-7577)
- Yipei Song (ORCID: https://orcid.org/0009-0004-4906-3026)
- Danchen Wang (ORCID: https://orcid.org/0000-0003-2688-3203)
- Xiang Zheng (ORCID: https://orcid.org/0000-0003-2442-9816)
- Yangyang Li (ORCID: https://orcid.org/0000-0001-8136-9130)
Institutions
- Nanchang University (CN)
- Jinan University (CN)
- Shenzhen Sixth People's Hospital (CN)
- Zhuhai People's Hospital (CN)
- ShenZhen People’s Hospital (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- First Affiliated Hospital of Jinan University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1638173
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China